Press releasePRNewswire
ADC Therapeutics SA
ADCT · NYSE
$1.52+$0.08 (+5.56%)TodayMarket closed ·
Prev close $1.44
Latest news
- Press releasePRNewswire
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
- News
ADC Therapeutics Q2 2026 Earnings Call Transcript
- Press releasePRNewswire
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
- Press releasePRNewswire
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
- NewsPiero Cingari
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why
- Press releasePRNewswire
ADC Therapeutics Announces New Employee Inducement Grant
- News
ADC Therapeutics Completes Enrollment In LOTIS-7 Phase 1b Open-Label Clinical Trial Evaluating ZYNLONTA In Combination With Bispecific Antibody Glofitamab In Patients With R/R Diffuse Large B-Cell Lymphoma
- Press releasePRNewswire
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
- News
ADC Therapeutics Announces Strategic Reorganization To Focus Resources Behind Key Value-Driving Initiatives In Support Of ZYNLONTA Franchise
- Press releasePRNewswire
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA – ADCT
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
- NewsKaustubh Bagalkote
Why Is ADC Therapeutics Stock Falling On Friday?
- NewsVandana Singh
Why Is ADC Therapeutics Stock Falling Thursday?
- Press releasePRNewswire
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- News
Full Transcript: ADC Therapeutics Q1 2026 Earnings Call
- Press releasePRNewswire
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
- News
Earnings Scheduled For May 4, 2026
- Press releasePRNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- Press releasePRNewswire
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
- Press releasePRNewswire
ADC Therapeutics Announces New Employee Inducement Grant
- News
ADC Therapeutics: Q4 Earnings Insights
- Press releasePRNewswire
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
- News
Earnings Scheduled For March 10, 2026
- News
What to Expect from ADC Therapeutics's Earnings
- Press releasePRNewswire
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
- Press releasePRNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- Press releasePRNewswire
ADC Therapeutics to Participate in March Investor Conferences
- Press releasePRNewswire
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
- Press releasePRNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- Press releasePRNewswire
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
- NewsAvi Kapoor
Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- NewsAvi Kapoor
Crude Oil Gains 1%; Macy's Reports Strong Q3 Results
- News
Earnings Scheduled For November 10, 2025
- News
Earnings Preview For ADC Therapeutics
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.